Abstract
Objectives: The effect of vedolizumab on postoperative outcomes in patients with inflammatory bowel disease (IBD) remains unclear. We aimed to determine the relation between preoperative vedolizumab and early postoperative complications in patients with IBD undergoing abdominal surgery.
Methods: A search of databases and abstracts from gastroenterology conferences was performed. Primary outcomes included overall and infectious postoperative complication rates as well as surgical site infections. Studies that compared Crohn disease, ulcerative colitis, or patients with IBD-undefined with preoperative vedolizumab treatment undergoing abdominal surgery with controls with preoperative antitumor necrosis factor-α (anti-TNF-α) treatment or no preoperative biologic treatment were included. A meta-analysis was completed using the Mantel-Haenszel and DerSimonian and Laird models.
Results: Six studies totaling 1201 patients were included; 281 patients were treated preoperatively with vedolizumab, 327 patients were treated preoperatively with anti-TNF-α agents, and 593 patients were not treated preoperatively with any biologics. There was no significant difference in overall complications (odds ratio [OR] 1.04, 95% confidence interval [CI] 0.48–2.24, P = 0.92, I2 =77%) between the vedolizumab and no-biologic groups. There also was no significant difference in infectious complications (OR 1.00, 95% CI 0.37–2.69, P = 1.00, I2 = 78%), which persisted after sensitivity analysis (OR 0.71, 95% CI 0.31–1.60, P = 0.41, I2 = 46%). Furthermore, there was no significant difference in overall complications (OR 0.77, 95% CI 0.24–2.46, P = 0.66, I2 = 85%) and infectious complications (OR 0.89, 95% CI 0.20–3.94, P = 0.87, I2 = 86%) between the vedolizumab and anti-TNF-α groups. After sensitivity analysis, differences in overall and infectious complications remained insignificant (OR 0.54 and 0.50, 95% CI 0.24–1.17 and 0.22–1.15, P = 0.12 and 0.10, I2 = 39% and 18%, respectively). Vedolizumab was also not associated with a significant increase in surgical site infections compared with the no-biologic (OR 1.45, 95% CI 0.33–6.32, P = 0.62, I2 = 75%) and anti-TNF (OR 1.30, 95% CI 0.22–7.60, P = 0.77, I2 = 81%) groups.
Conclusions: Preoperative treatment with vedolizumab in patients with IBD undergoing abdominal surgery is not associated with increases in overall or infectious postoperative complications compared with preoperative anti-TNF-α treatment and no preoperative biologic treatment. Large, prospective studies are needed to further assess the impact of preoperative vedolizumab treatment on postoperative complications, particularly with respect to IBD subtype.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
1. Ramos GP, Papadakis KA. Mechanisms of disease: inflammatory bowel diseases. Mayo Clin Proc 2019;94:155–165.
2. Aniwan S, Park SH, Loftus EV. Jr. Epidemiology, natural history, and risk stratification of Crohn’s disease. Gastroenterol Clin North Am 2017;46:463–480.
3. Aarons CB. Laparoscopic surgery for Crohn disease: a brief review of the literature. Clin Colon Rectal Surg 2013;26:122–127.
4. Hwang JM, Varma MG. Surgery for inflammatory bowel disease. World J Gastroenterol 2008;14:2678–2690.
5. Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut 2017;66:839–851.
6. Khanna R, Mosli MH, Feagan BG. Anti-integrins in ulcerative colitis and Crohn’s disease: what is their place? Dig Dis 2016;34:153–159.
7. Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn’s disease and ulcerative colitis. Therap Adv Gastroenterol 2016;9:330–338.
8. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013;369:711–721.
9. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699–710.
10. Lightner AL, Raffals LE, Mathis KL, et al. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohns Colitis 2017;11:185–190.
11. Law CC, Narula A, Lightner AL, et al. Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. J Crohns Colitis 2018;12:538–545.
12. Yung DE, Horesh N, Lightner AL, et al. Systematic review and metaanalysis: vedolizumab and postoperative complications in inflammatory bowel disease. Inflamm Bowel Dis 2018;24:2327–2338.
13. Zimmerman LA, Zalieckas JM, Shamberger RC, et al. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. J Pediatr Surg 2018;53:1330–1333.
14. Zimmerman L, Zalieckas J, Shamberger R, et al. Postoperative complications in patients with inflammatory bowel disease treated with vedolizumab. Paper presented at World Congress of Pediatric Gastroenterology, Hepatology and Nutrition; Montreal, QC, Canada; October 5–8, 2016.
15. Lightner AL, Sang Tse C, Potter DD Jr, et al. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease. J Pediatr Surg 2018;53:1706–1709.
16. Lightner A, Mathis K, Sang Tse C, et al. Postoperative outcomes in vedolizumab-treated patients undergoing major abdominal operations for inflammatory bowel disease: retrospective multi-center cohort study. Inflamm Bowel Dis 2018;24:871–876.
17. Ferrante M, de Buck van Overstraeten A, Schils N, et al. Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohns Colitis
2017;11:1353–1361.
18. Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol 2017;112:1423–1429.
19. Schils N, De Buck Van Overstraeten A, Vermeire S, et al. Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn’s disease undergoing right hemicolectomy with ileocolonic anastomosis. J Crohns Colitis 2017;11(suppl 1):S304.
20. Shen B, Blake A, Lasch K, et al. Vedolizumab use in patients with IBD undergoing surgery: a summary from clinical trials and post-marketing experience. Inflamm Bowel Dis 2017;23:S47.
21. Stringfeld S, Parry L, Sandborn W, et al. Patients on vedolizumab have a high rate of postoperative complications. Paper presented at American Society of Colon and Rectal Surgeons; Los Angeles, CA; April 30–
May 4, 2016.
22. Zangenberg MS, Horesh N, Kopylov U, et al. Preoperative optimization of
patients with inflammatory bowel disease undergoing gastrointestinal
surgery: a systematic review. Int J Colorectal Dis 2017;32:1663–1676.
23. Ferrante M, D’Hoore A, Vermeire S, et al. Corticosteroids but not infliximab
increase short-term postoperative infectious complications in patients with
ulcerative colitis. Inflamm Bowel Dis 2009;15:1062–1070.
24. Ritsu M, Kawakami K, Kanno E, et al. Critical role of tumor necrosis factorα in the early process of wound healing in skin. J Dermatol Dermatol Surg 2017;21:14–19.
25. Schleier L, Wiendl M, Binder M, et al. α4β7 integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages. J Crohns Colitis 2018;12(suppl 1):S005–S007.
26. Vaid S, Bell T, Grim R, et al. Predicting risk of death in general surgery patients on the basis of preoperative variables using American College of Surgeons National Surgical Quality Improvement Program data. Permanente J 2012;16:10–17.
27. Yang Z, Wu Q, Wu K, et al. Meta-analysis: effect of preoperative infliximab use on early post-operative complications in patients with ulcerative colitis undergoing abdominal surgery. Aliment Pharmacol Ther 2012;36:922–928.
28. Cohen BL, Fleshner P, Kane SV, et al. Anti-tumor necrosis factor therapy is not associated with post-operative infection: results from prospective cohort of ulcerative colitis and Crohn’s disease patients undergoing surgery to identify risk factors for postoperative infection I (PUCCINI). Gastroenterology 2019;156:S–80.
29. Narula N, Charleton D, Marshall JK. Meta-analysis: peri-operative anti-tnfα treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;37:1057–1064.
30. Billioud V, Ford AC, Tedesco ED, et al. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a metaanalysis. J Crohns Colitis 2013;7:853–867.
31. Yang ZP, Hong L, Wu Q, et al. Preoperative infliximab use and postoperative complications in Crohn’s disease: a systematic review and meta-analysis. Int J Surg 2014;12:224–230.
32. Rosenfeld G, Qian H, Bressler B. The risks of post-operative complications following pre-operative infliximab therapy for Crohn’s disease in patients undergoing abdominal surgery: a systematic review and meta-analysis. J Crohns Colitis 2013;7:868–877.
